Back to Clinical Trials

Brief Title: Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study

Sacral Nerve Stimulation for Low Anterior Resection Syndrome or Fecal Incontinence in Patients Following a Low Anterior Resection or Proctectomy With Coloanal Anastomosis or in Patients After Pelvic Chemoradiation (RESTORE)

INTRODUCTION

  • Org Study ID: 2016-0754
  • Secondary ID: NCI-2019-02649, 2016-0754, P30CA016672
  • NTC ID: NCT04066894
  • Sponsor: M.D. Anderson Cancer Center
MD Anderson Cancer Center Website

BRIEF SUMMARY

This trial studies how well sacral nerve stimulation works in treating low anterior resection syndrome or fecal incontinence (the body's passage of stool without control) in patients with rectal cancer that has spread to nearby tissues or lymph nodes, or other pelvic cancer. Sacral nerve stimulation is a permanent implant that may improve bowel functions by stimulating the nerves that control the muscles related to bowel function.

DETAILED DESCRIPTION

PRIMARY OBJECTIVES:

I. To investigate the efficacy of sacral nerve stimulator placement in patients with fecal incontinence (FI) or low anterior resection syndrome (LARS) who have previously undergone chemoradiation treatment and/or a restorative partial or complete proctectomy with colorectal or coloanal anastomosis for cancer treatment as per standard of care (restorative surgery cohort).

II. To evaluate the feasibility of sacral nerve stimulator placement in patients with fecal incontinence (FI) or other defecatory dysfunction who have received pelvic radiation treatment without undergoing rectal or other pelvic surgery as per standard of cancer care (radiation only cohort).

SECONDARY OBJECTIVES:

I. To evaluate the effectiveness of sacral nerve stimulation (SNS) as measured by validated questionnaires in patients with FI or LARS within both patient cohorts.

II. To evaluate pelvic floor and sphincter physiology using anorectal manometry (ARM) before and after SNS in patients with FI or LARS within both patient cohorts.

III. To assess potential impact of SNS on urinary incontinence measuring a post-void urinary bladder residual and validated urinary symptom questionnaires in both patient cohorts.

IV. To assess efficacy of SNS on long-term bowel dysfunction at 1 and 3 years post battery implantation as measured by validated questionnaires for both patient cohorts.

OUTLINE:

Patients undergo scheduled, elective surgery for placement of the sacral nerve stimulator with external battery pack. After 2 weeks, patients undergo implantation of a subcutaneous internal battery or removal of the leads if the sacral nerve stimulator is working but does not improve symptoms. If the sacral nerve stimulator is not working, it is repositioned and patients return 2 weeks later for implantation of external battery or removal of leads.

After completion of study, patients are followed up at 1 month, 1 year, and 3 years.

  • Overall Status
    Recruiting
  • Start Date
    April 12, 2019
  • Phase
    Not Applicable
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Proportion of patients with Sacral nerve stimulation (SNS) success

Primary Outcome 1 - Timeframe: up to 2 weeks (+7) days post SNS placement

CONDITION

  • Fecal Incontinence
  • Low Anterior Resection Syndrome
  • Malignant Anal Neoplasm
  • Malignant Bladder Neoplasm
  • Malignant Cervical Neoplasm
  • Malignant Ovarian Neoplasm
  • Malignant Pelvic Neoplasm
  • Malignant Prostate Neoplasm
  • Malignant Uterine Neoplasm
  • Malignant Vaginal Neoplasm
  • Malignant Vulvar Neoplasm
  • Rectal Adenocarcinoma
  • Stage III Rectal Cancer AJCC v8
  • Stage IIIA Rectal Cancer AJCC v8
  • Stage IIIB Rectal Cancer AJCC v8
  • Stage IIIC Rectal Cancer AJCC v8
  • Stage IV Rectal Cancer AJCC v8
  • Stage IVA Rectal Cancer AJCC v8
  • Stage IVB Rectal Cancer AJCC v8
  • Stage IVC Rectal Cancer AJCC v8

ELIGIBILITY

Inclusion Criteria:
Cohort 1: Patients with pathologically proven diagnosis of primary rectal cancer

- Cohort 1: Patients who have previously undergone surgical resection and anastomosis (restorative) with curative intent treatment with or without chemoradiation

- Cohort 1: Patients with T1 and T2 pathologic stage patients treated with restorative surgical resection without radiation

- Cohort 1: Patients with locally advanced rectal adenocarcinoma (T3 and T4 or lymph node positive) treated with radiation and restorative surgery

- Cohort 1: Patients with self-reported FI or LARS

- Cohort 1: Patients must be able to speak and understand English

- Cohort 1: Patients must be willing to and able to sign an approved informed consent document

- Cohort 1: Patients must be >= 24 months post-resection of rectal cancer

- Cohort 1: Patients must have failed prior conservative measures such as Metamucil and motility medications and already been assessed and treated in a pelvic floor rehabilitation program (biofeedback) designed to treat FI and LARS, and continue to experience significant defecatory dysfunction, allowable per principal investigator (PI) discretion

- Cohort 1: Patients must be willing and able to complete Patient Reported Outcomes Questionnaires for before device placement, during the testing phase following lead placement, and after implantation of the battery

- Cohort 1: Patients must be willing and able to undergo elective ARM testing to objectively measure pelvic floor function

- Cohort 1: Patients who have an average resting tone < 40 mmHg (normal > 40 mmHg) and maximal tolerance < 200 milliliters (normal 200-300 milliliters) as measured by ARM - Cohort 2: Patients with pathologically proven malignancy of the pelvis, other than rectal cancer (e.g. prostate, bladder, anus, vagina, vulva, cervix, uterus, or ovary) - Cohort 2: Patients treated with standard of care radiation therapies without surgical resection - Cohort 2: Patients with self-reported FI or other defecatory dysfunction - Cohort 2: Patients must be able to speak and understand English - Cohort 2: Patients must be willing to and able to sign an approved informed consent document - Cohort 2: Patients must be >= 18 months post-pelvic chemoradiation

- Cohort 2: Patients must have already been assessed and treated in a pelvic floor rehabilitation program design to treat FI or other defecatory dysfunction and continue to experience significant defecatory dysfunction

- Cohort 2: Patients must be willing and able to complete Patient Reported Outcomes (PROs) and bowel and bladder diaries (Medtronic) at multiple times during the study

- Cohort 2: Patients must be willing and able to undergo elective ARM testing to measure pelvic floor function

- Cohort 2: Patients who have an average resting tone < 40 mmHg (normal > 40 mmHg) and maximal tolerance < 200 milliliters (normal 200-300 milliliters) as measured by ARM
Exclusion Criteria:
Cohort 1: Patients with co-morbid illnesses or concurrent disease, which in the judgment of the clinician obtaining informed consent, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

- Cohort 1: Any diverting bowel ostomy at the time of consent to this study

- Cohort 1: Patients with an absolute neutrophil count (ANC) < 1.7 within 30 days of consent - Cohort 1: Patients with an international normalized rate (INR) > 1.3 within 30 days of consent

- Cohort 1: Patients with a platelet count < 50 K within 30 days of consent - Cohort 1: Patients currently being treated with chemotherapy or within preceding 30 days at the time consent - Cohort 1: Patients previously treated with a SNS for urinary or FI - Cohort 1: Patients who were documented to have an anastomotic leak following their restorative surgical resection - Cohort 1: Patients with an Eastern Cooperative Oncology Group (ECOG) performance status > 2 at the time of consent

- Cohort 1: Patients with an active infection requiring systemic therapy at the time of consent

- Cohort 1: Patients with a significant history of uncontrolled cardiac disease including, but not limited to hypertension, unstable angina, myocardial infarction within the last 4 months, and uncontrolled congestive heart failure

- Cohort 2: Co-morbid illnesses or other concurrent disease, which in the judgment of the clinician obtaining informed consent, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

- Cohort 2: Patients with an ANC < 1.7 within 30 days of consent - Cohort 2: Patients with an INR > 1.3 within 30 days of consent

- Cohort 2: Patients with a platelet count < 50 K, within 30 days of consent - Cohort 2: Patients currently being treated with chemotherapy or within the preceding 30 days at the time of consent - Cohort 2: Patients previously treated with a sacral nerve stimulator for urinary or fecal incontinence - Cohort 2: Patients with an ECOG performance status > 2 at the time of consent

- Cohort 2: Patients with an active infection requiring systemic therapy at the time of consent

- Cohort 2: Patients with a significant history of uncontrolled cardiac disease including, but not limited to hypertension, unstable angina, myocardial infarction within the last 4 months, and uncontrolled congestive heart failure

- Cohort 2: Patients with an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study

- Cohort 2: Patients who are human immunodeficiency virus (HIV) positive (+) or have hepatitis B or C remain eligible, however, HIV+ patients must have a CD4 T cell count > 200 cells per microliter

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Craig A Messick

Role: Principal Investigator

Affiliation: M.D. Anderson Cancer Center

Overall Contact

Name: Craig A Messick

Phone: N/A

Email: N/A

LOCATION

Facility Status Contact
Facility: M D Anderson Cancer Center
Houston, Texas 77030
United States
Status: Recruiting Contact: Contact
Craig A. Messick
713-792-6940
cmessick@mdanderson.org
Facility: MD Anderson in Sugar Land
Sugar Land, Texas 77478
United States
Status: Recruiting Contact: Principal Investigator
Craig A. Messick
713-792-6940
cmessick@mdanderson.org2016-0754